In addition, IU LAB announced that its accelerator programs will now be called IU Health Incubator at IU LAB, thanks to a $4.5 million, three-year sponsorship deal with IU Health.
Read More
It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another billion-dollar deal or investment.
Read More
PhysioLogic Devices Inc. will change its name to Portal Diabetes Inc. following the company’s move. It plans to employ up to 35 full-time employees by 2028 with an average salary of $135,265 each.
Read More
Cook Biotech employs 275 people, all of whom will transition to RTI Surgical once the deal closes.
Read More
Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the Indianapolis-based drugmaker broke ground on this week.
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
The pre-clinical West Lafayette-based medical device startup is working to develop a new “microstructred” catheter to remove blood clots that cause strokes.
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Indianapolis-based Gate Neurosciences, which is in clinical trials of a medicine to treat depression, plans to acquire California-based biotech startup Boost Neuroscience.
The National Institutes of Health said the change would save more than $4 billion a year, effective immediately.
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its next big steps: regulatory approval and commercial launch.
The five-year-old company is developing treatments for endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity. Its positive reception on Wall Street was seen as an extension of the general enthusiasm for obesity treatments.
MBX is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity.
The AgriNovus Indiana report quantifies agbiosciences as contributing $22.7 billion to the state’s gross domestic product. It also identifies several key areas of opportunity for growth in this sector.
State and corporate leaders believe a tech park taking shape on the western edge of downtown could be a launchpad for health sciences innovation and commercialization as part of the state’s ambitious economic development portfolio.
Stevanato, an Italian-based life sciences company that makes glass vials and syringes for pharmaceuticals, has committed to paying employees at its new Fishers facility no less than $70,000 annually.
Indiana’s Heartland BioWorks Hub was one of 12 hubs chosen to split $500 million in implementation funding stemming from the CHIPS and Science Act.
A report issued Monday by BioCrossroads says Indiana life sciences companies saw a decrease in capital and investments last year, but made a significantly higher contribution to the state’s economy than they did the previous year.
Indianapolis-based NICO recently wrapped up a large clinical trial that tested the company’s minimally invasive tools and technology for brain surgery in patients with hemorrhagic stroke. Now it faces a major decision.
The Greenfield-based maker of animal vaccines, antibiotics and other health products said that as part of the agreement with Ancora Holding Inc., it will appoint two new independent directors supported by the investment firm to its board.
The company said the restructuring is designed to shift resources from its farm animal operations to its pet health operations and help with the launch of three upcoming products now under regulatory review.
About 37 million American have diabetes, which requires close monitoring of blood sugar levels. A doctor said using the unapproved devices could result in inaccurate blood sugar measurements, with potentially devastating consequences.
The Boston-based biotech company with large operations in Indiana has raised more than a half-billion dollars over its eight-year history.
